Literature DB >> 34168323

Initial evidence of research quality of registered reports compared with the standard publishing model.

Courtney K Soderberg1, Timothy M Errington1, Sarah R Schiavone2, Julia Bottesini2, Felix Singleton Thorn3, Simine Vazire2,3, Kevin M Esterling4, Brian A Nosek5,6.   

Abstract

In registered reports (RRs), initial peer review and in-principle acceptance occur before knowing the research outcomes. This combats publication bias and distinguishes planned from unplanned research. How RRs could improve the credibility of research findings is straightforward, but there is little empirical evidence. Also, there could be unintended costs such as reducing novelty. Here, 353 researchers peer reviewed a pair of papers from 29 published RRs from psychology and neuroscience and 57 non-RR comparison papers. RRs numerically outperformed comparison papers on all 19 criteria (mean difference 0.46, scale range -4 to +4) with effects ranging from RRs being statistically indistinguishable from comparison papers in novelty (0.13, 95% credible interval [-0.24, 0.49]) and creativity (0.22, [-0.14, 0.58]) to sizeable improvements in rigour of methodology (0.99, [0.62, 1.35]) and analysis (0.97, [0.60, 1.34]) and overall paper quality (0.66, [0.30, 1.02]). RRs could improve research quality while reducing publication bias and ultimately improve the credibility of the published literature.
© 2021. The Author(s), under exclusive licence to Springer Nature Limited.

Entities:  

Mesh:

Year:  2021        PMID: 34168323     DOI: 10.1038/s41562-021-01142-4

Source DB:  PubMed          Journal:  Nat Hum Behav        ISSN: 2397-3374


  11 in total

1.  Questionable Research Practices, Low Statistical Power, and Other Obstacles to Replicability: Why Preclinical Neuroscience Research Would Benefit from Registered Reports.

Authors:  Randall J Ellis
Journal:  eNeuro       Date:  2022-08-03

Review 2.  Open and reproducible science practices in psychoneuroendocrinology: Opportunities to foster scientific progress.

Authors:  Maria Meier; Tina B Lonsdorf; Sonia J Lupien; Tobias Stalder; Sebastian Laufer; Maurizio Sicorello; Roman Linz; Lara M C Puhlmann
Journal:  Compr Psychoneuroendocrinol       Date:  2022-05-30

3.  Why ex post peer review encourages high-risk research while ex ante review discourages it.

Authors:  Kevin Gross; Carl T Bergstrom
Journal:  Proc Natl Acad Sci U S A       Date:  2021-12-21       Impact factor: 12.779

4.  Future Directions for Chemosensory Connectomes: Best Practices and Specific Challenges.

Authors:  Maria G Veldhuizen; Cinzia Cecchetto; Alexander W Fjaeldstad; Michael C Farruggia; Renée Hartig; Yuko Nakamura; Robert Pellegrino; Andy W K Yeung; Florian Ph S Fischmeister
Journal:  Front Syst Neurosci       Date:  2022-05-30

5.  Improving medical research in the United Kingdom.

Authors:  Stephen H Bradley; Nicholas J DeVito; Kelly E Lloyd; Patricia Logullo; Jessica E Butler
Journal:  BMC Res Notes       Date:  2022-05-13

6.  Trinity review: integrating Registered Reports with research ethics and funding reviews.

Authors:  Yuki Mori; Kaito Takashima; Kohei Ueda; Kyoshiro Sasaki; Yuki Yamada
Journal:  BMC Res Notes       Date:  2022-05-19

7.  Reporting all results efficiently: A RARE proposal to open up the file drawer.

Authors:  David D Laitin; Edward Miguel; Ala' Alrababa'h; Aleksandar Bogdanoski; Sean Grant; Katherine Hoeberling; Cecilia Hyunjung Mo; Don A Moore; Simine Vazire; Jeremy Weinstein; Scott Williamson
Journal:  Proc Natl Acad Sci U S A       Date:  2021-12-28       Impact factor: 11.205

8.  From grassroots to global: A blueprint for building a reproducibility network.

Authors: 
Journal:  PLoS Biol       Date:  2021-11-10       Impact factor: 8.029

9.  Premiering pre-registration at PLOS Biology.

Authors:  Nonia Pariente
Journal:  PLoS Biol       Date:  2022-03-31       Impact factor: 8.029

10.  Challenges for assessing replicability in preclinical cancer biology.

Authors:  Timothy M Errington; Alexandria Denis; Nicole Perfito; Elizabeth Iorns; Brian A Nosek
Journal:  Elife       Date:  2021-12-07       Impact factor: 8.140

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.